Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studiesDafna D. Gladman, Philip J. Mease, Nikolay Delev et al.|RMD Open|2018Cited by 38
Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled TrialsPhilip J. Mease, J. Wollenhaupt, Dafna D. Gladman et al.|ACR Open Rheumatology|2020Cited by 21
SAT0408 Long-Term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase 3, Randomized, Controlled TrialsPhilip J. Mease, C. Birbara, Arthur Kavanaugh et al.|Annals of the Rheumatic Diseases|2014Cited by 17
SAT0436 Durability of apremilast response in patients with psoriatic arthritis: long-term (208-week) results from the palace 1 trialArthur Kavanaugh, J. Wollenhaupt, Gladman Dd et al.|Annals of the Rheumatic Diseases|2017Cited by 0